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Abstract
Background: The molecular mechanisms of cell cycle exit are poorly understood. Studies on
lymphocytes at cell cycle exit after growth factor deprivation have predominantly focused on the
initiation of apoptosis. We aimed to study gene expression profile of primary and immortalised IL-
2-dependent human T cells forced to exit the cell cycle by growth factor withdrawal, before
apoptosis could be evidenced.
Results:  By the Affymetrix microarrays HG-U133 2.0 Plus, 53 genes were distinguished as
differentially expressed before and soon after IL-2 deprivation. Among those, PIM1, BCL2, IL-8,
HBEGF, DUSP6, OSM, CISH, SOCS2, SOCS3, LIF and IL13 were down-regulated and RPS24, SQSTM1,
TMEM1, LRRC8D, ECOP, YY1AP1, C1orf63, ASAH1, SLC25A46 and MIA3 were up-regulated. Genes
linked to transcription, cell cycle, cell growth, proliferation and differentiation, cell adhesion, and
immune functions were found to be overrepresented within the set of the differentially expressed
genes.
Conclusion: Cell cycle exit of the growth factor-deprived T lymphocytes is characterised by a
signature of differentially expressed genes. A coordinate repression of a set of genes known to be
induced during T cell activation is observed. However, growth arrest following exit from the cell
cycle is actively controlled by several up-regulated genes that enforce the non-dividing state. The
identification of genes involved in cell cycle exit and quiescence provides new hints for further
studies on the molecular mechanisms regulating the non-dividing state of a cell, the mechanisms
closely related to cancer development and to many biological processes.
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Background
Cell growth, proliferation and arrest mechanisms are cru-
cial for development and homeostasis. Extensive studies
have examined the mechanisms of cell activation and cell
cycle progression, which involve sequential effects of
growth factors and their receptors and activation of intra-
cellular signal transduction pathways, transcription fac-
tors, cyclins and cyclin-dependent kinases [1]. Studies on
lymphocytes withdrawn from the cell cycle have focused
on the initiation of apoptosis following growth factor
deprivation [2-8] or on the cell-to-cell contact mecha-
nisms that prevent cells from apopotosis [9-11]. Still, the
molecular mechanisms of cell cycle exit remain poorly
understood. With the lack of mitogenic signals, and in
response to antiproliferative signals such as mitogen with-
drawal, growth factor starvation, contact inhibition or
DNA damage, a proliferating cell arrests to become quies-
cent (a reversible, nondividing state) or senescent, or to
undergo apoptotic death. Most somatic cells in an adult
body remain in a postmitotic G0 phase. However, during
tissue regeneration and repair, wound healing and
immune response, cells re-enter the cell cycle and subse-
quently withdraw from proliferation.
Studies in lymphocytes and fibroblasts have shown that
resting cells are not in a passive state resulting simply from
the lack of stimulation. Pajalunga et al. [12] summarized
cell cycle exit as "a shift in the balance between positive
and negative regulators of proliferation in favour of the
latter". Indeed, resting cells were found to express sets of
up-regulated and down-regulated genes that maintained
an active state of non-division [1,12,13,15,16]. A group of
genes required for cell cycle exit and the maintenance of
cell quiescence in human fibroblasts following serum
deprivation has been recently identified [17]. Compara-
tive studies of transcriptional profiles of resting and stim-
ulated lymphocytes [1,18] have shown that T lymphocyte
quiescence is actively maintained by products of a set of
genes, including TOB and KLF (LKLF, GKLF and BKLF)
and FOXO families of transcription factors. Other candi-
date genes involved in lymphocyte quiescence, including
TSC-22 and Dyrk1, have been identified in a mouse model
among genes highly expressed in resting lymphocytes and
down-regulated after T or B cell activation [1].
The present study on a human T cell model may provide
new insights into the molecular changes involved in cell
proliferation control, cell cycle exit and cellular quies-
cence. Cellular quiescence represents an important safe-
guard against tumorigenesis; therefore the identification
of quiescence-controlling genes and a better understand-
ing of the relevant molecular pathways may open new
possibilities in cancer diagnosis and treatment. Thus, in
our study, proliferating interleukin (IL)-2-dependent
human T cells were forced to exit cell cycle by growth fac-
tor withdrawal, and their gene expression profiles were
examined.
Results and discussion
To gain new insights into cell cycle exit of T lymphocytes,
we performed gene expression profiling in human IL-2-
dependent T lymphoblasts deprived of the growth factor.
Following IL-2 withdrawal, IL-2-dependent, proliferating
T lymphoblasts cease to divide and undergo apoptosis
[19]. Therefore, transcription profiles of T cells were ana-
lysed soon after IL-2 withdrawal (8 hours), before apop-
totic changes could be observed. In addition, to minimize
effects associated with the heterogeneity of primary T cell
populations, we also studied clonal populations of
immortalised IL-2-dependent T lymphoblasts and looked
for the common changes in the two cellular models. We
believe that this approach also limited the "non-specific"
gene expression changes in the primary IL-2-deprived T
lymphoblasts, i.e. not related to IL-2 withdrawal, but
rather to the possible paracrine signalling in polyclonal
populations by other cytokines characterised by a redun-
dant activity.
Five cell lines were subjected to IL-2 deprivation and
microarray analysis, three primary, IL-2-dependent T lym-
phoblast lines derived from three different donors
(denoted "6", "43" and "j") and two immortalised T cell
lines (denoted line 5 and S9), examined in three biologi-
cal replicates each. Altogether, 18 microarray hybridisa-
tions were performed.
In the first step, unsupervised Principal Component Anal-
ysis was performed to assess the reliability of the experi-
ments. Biological replicates were shown to cluster
together. The gene expression profile of all the analysed
cell lines was shown to be affected by IL-2 withdrawal, but
the major variability of the gene expression profile in the
analysed dataset was found between primary and immor-
talised cell lines (unpublished data). Differences between
primary and immortalised cells were much greater than
those resulting from IL-2 withdrawal. Therefore, our anal-
ysis was carried out in a block design, and changes in gene
expression following IL-2 withdrawal were assessed sepa-
rately in primary and immortalised cell lines. By means of
the parametric non-corrected t-test we selected 158 differ-
entially expressed genes at p < 0.001 (see Additional File
1: Table A1 for genes differentiating between samples
before and after IL-2 withdrawal, selected by a non-paired
analysis). The probability of a random selection of such a
number of genes was low (0.03 in a global test) which
confirmed the reliability of the observed differences. A
false discovery rate for the selected genes ranged from
0.003 to 0.12. The hierarchical clustering of the 158 differ-
entially expressed probe-sets obtained in this analysis
resulted in an ideal discrimination between the samplesBMC Genomics 2009, 10:261 http://www.biomedcentral.com/1471-2164/10/261
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before and after IL-2 withdrawal, with a rather uniform
pattern of expression (Figure 1).
Having confirmed the statistical significance of differences
related to IL-2 withdrawal, we have selected the most con-
sistently changed genes in all five different cell lines ana-
lysed, by employing a paired analysis (of the
corresponding cells before and after IL-2 withdrawal). The
univariate non-corrected permutation test revealed 166
probe-sets changed significantly at P < 0.001 (while in a
global test, a borderline significance of P = 0.0625 was
obtained). A hundred and eight of these genes were
repressed after growth factor withdrawal, and the remain-
ing 58 were up-regulated (see Additional File 2: Table A2
for genes differentiating between samples before and after
IL-2 withdrawal, selected by a paired sample analysis).
Out of those, DUSP6, OSM, CISH, SOCS2, LIF and IL13
were found to be the most prominently down-regulated
(more than 20-fold), and the expression of EMB, SOX4,
RPS24, WNT5B, SLC1A4, SQSTM1, SUMF1, TMEM1,
STK38, LAMP2 and C17orf42 was found to be the most
increased (2-fold to 3.5-fold change).
We carried out an external validation of the results
obtained in the microarray analysis by a qRT-PCR. For val-
idation we used the same cell lines and we chose 8 genes
from the list of 158 most significantly changed transcripts,
and a further 4 genes, known for their interesting func-
tion, with lower significance of differences. Most of the
qRT-PCR results confirmed the microarray findings (Table
1): 7 of 8 top genes and 3 of 4 less significant transcripts
were confirmed in a qRT-PCR experiment, usually with a
similar fold-change.
To select transcripts consistently changed upon IL-2 with-
drawal, we combined the two lists of 166 and 158 signif-
icant genes, obtained in the paired and non-paired
analyses, respectively. We identified a set of 53 genes com-
prised of 13 up-regulated and 40 down-regulated genes,
which we designated a "T lymphocyte cell cycle exit signa-
ture" (Table 2).
The up-regulated genes identified after IL-2 deprivation in
both primary and immortalised cells included SQSTM1,
ECOP, YY1AP1, RPS24, TMEM1, LRRC8D, C1orf63,
ASAH1, SLC25A46 and MIA3, some of which have been
associated with cellular growth control.
The SQSTM1 protein, previously known as p62 protein,
interacts with the ubiquitinated proteins to mediate their
clearance and is an important scaffold molecule in the
RANK-NF-kappaB signalling pathway [20]. In addition,
while the p62 protein is also a ligand for Lck kinase of the
Src protein-tyrosine kinase family that is involved in T-cell
receptor-dependent activation [21], Köller et al. [22] stress
the role of Lck in transient T cell unresponsiveness, medi-
ated by a selective IL-2 deficiency. Thus, SQSTM1 may
play an important role in cell growth, especially because it
may facilitate cell survival through signalling cascades for
example those that result in Akt activation, by interaction
with protein kinase C, as shown in human neuronal cells
[23].
Interestingly, the product of the ECOP gene, which was
found here to be up-regulated, has also been previously
shown to be involved in NF-kappa B-related regulation of
cellular growth. ECOP (EGFR-Co-amplified and over-
expressed protein) has been implicated as a key regulator
in the NF-kappaB signalling, and it has been postulated
that high-level, amplification-mediated ECOP expression,
such as that occurring in tumours with amplified EGFR,
could contribute to resistance to apoptosis [24].
The identified genes may as well be associated with other
cell proliferation pathways. For example, a product of the
YYAP1 gene, called YY1-associated protein, a co-activator
of the YY1 (Yin Yang 1) transcription factor (YYAP1), had
been initially identified as a long splice variant of HCC
(hepatocellular carcinoma)-specific protein encoded by
the  HCCA2  gene (HCC-associated gene 2). An over-
expression of HCCA2 has been found to lead to a cell cycle
arrest at G0/G1 phase and to an inhibition of cell prolifer-
ation [25].
For the other up-regulated genes distinguished in this
study, we could not identify links to the known mecha-
nisms of cell cycle arrest, but some of the genes have been
previously associated with different cancers. An over-
expression of ASAH1 has been found in different malig-
nant tumours, including prostate cancer, head and neck
squamous cell cancers and T-cell large granular lym-
phocyte (LGL) leukaemia [26-28]. An inhibition of acid
ceramidase, the product of ASAH1, the over-expression of
which in cancer cells has been implicated in drug resist-
ance, is suggested as an efficient and promising novel
treatment strategy [29,30]. The ribosomal protein gene
RPS24 has been associated with hepatocellular carcinoma
[14]. The MIA3 (TANGO) protein has been identified as a
tumour suppressor in malignant melanoma and in colon
and hepatocellular carcinomas [31,32].
Out of genes encoding for the suggested crucial regulators
of T lymphocyte quiescence, such as TOB and members of
the KLF and FOXO transcription factors' families, as well
as TSC-22 and Dyrk1, which had previously been found to
be overexpressed in resting T cells [1,18,33-35], we only
found the FOXO3 gene to be slightly, but significantly up-
regulated after IL-2 withdrawal. This discrepancy might be
explained by differences between the different cell models
employed (mouse vs. human) and by different experi-BMC Genomics 2009, 10:261 http://www.biomedcentral.com/1471-2164/10/261
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Hierarchical clustering analysis based on the expression values of 158 probesets differentiating samples before and after IL-2  withdrawal in the non-paired analysis Figure 1
Hierarchical clustering analysis based on the expression values of 158 probesets differentiating samples before 
and after IL-2 withdrawal in the non-paired analysis. Samples before IL-2 withdrawal are in the light-blue columns, sam-
ples after IL-2 withdrawal in the navy-blue columns. Primary samples are in the yellow column, immortalised samples are in the 
green one. The names of the genes of the "T lymphocyte cell cycle exit signature" (Table 2) are marked.B
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Table 1: Validation of the selected microarray data by the qRT-PCR.
Rank Gene 
symbol
Description Probe set Signal Log Ratio (microarray analysis) Micorarray
Fold-change
(after/before
IL2 withdrawal)
Parametric
p-value
(non-paired
comparison)
qRT-PCR 
Fold 
change
qRT-PCR p-value 
(non-paired)
j 43 6 line 5 S9
genes with P < 0.0001 in the microarray gene expression analysis
2 CISH cytokine inducible SH2-containing 
protein
223377_x_at -5.01 -4.936 -5.435 -4.649 -4.519 0.03 <0.0001 0.08 <0.0001
7 DUSP6 dual specificity phosphatase 6 208893_s_at -6.236 -5.771 -5.75 -4.873 -5.028 0.02 <0.0001 0.04 <0.0001
11 C3orf59 chromosome 3 open reading frame 59 227599_at -3.035 -2.559 -2.647 -2.401 -2.29 0.17 <0.0001 0.32 0.0082
18 ASAH1 N-acylsphingosine amidohydrolase 
(acid ceramidase) 1
213702_x_at 0.726 0.671 0.612 0.569 0.787 1.59 <0.0001 2.08 0.0069
genes with P < 0.001 in the microarray gene expression analysis
33 SOCS2 suppressor of cytokine signaling 2 203373_at -4.178 -4.954 -5.332 -3.528 -4.438 0.04 0.0001 0.12 0.0058
45 OSM oncostatin M 214637_at -4.201 -4.671 -3.352 -4.564 -5.351 0.04 0.0002 0.04 0.0011
66 IL8 interleukin 8 211506_s_at -3.537 -2.395 -3.14 -4.011 -3.575 0.10 0.0003 0.19 0.2333
92 HBEGF heparin-binding EGF-like growth 
factor
203821_at -5.121 -3.605 -4.72 -3.679 -3.178 0.06 0.0004 0.08 0.0001
genes with P < 0.01 in the microarray gene expression analysis
221 MT1F metallothionein 1F 217165_x_at 2.408 1.794 1.091 2.344 2.002 3.80 0.0013 7.05 0.0004
348 MT1X metallothionein X 208581_x_at 2.066 1.764 0.997 2.656 2.005 3.73 0.0021 4.76 0.0004
514 CLK4 CDC-like kinase 4 210346_s_at 1.399 1.014 1.729 1.188 0.576 2.27 0.0036 2.41 0.0046
600 IL7R interleukin 7 receptor 205798_at 1.923 0.919 1.965 2.962 1.721 3.73 0.0043 3.19 0.2734BMC Genomics 2009, 10:261 http://www.biomedcentral.com/1471-2164/10/261
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mental settings. On the other hand, the activity of these
transcription factors may be regulated posttranscription-
ally, so that their mRNA levels may not necessarily reflect
their activity. Thus, the expression of some of the known
FOXO target genes was examined and found to be affected
following IL-2 withdrawal. IL7R, the FOXO1 target gene
was up to 4-fold overexpressed in the primary T lym-
phocytes, but not in immortalised T cells. CDKN1B (p27),
another FOXO target in human, mouse and C. elegans
models [1,34-37], encoding a cell-cycle regulatory pro-
tein, presented slightly, but significantly increased expres-
sion. Similarly, Pink1, a recently identified FOXO target,
the product of which helps to protect lymphocytes from
apoptosis after growth factor deprivation [38], was among
genes of significantly elevated expression in our model of
cell-cycle exit. Studies of Murphy [36] on C. elegans
model pointed at metallothionein genes as possible
FOXO targets. In the present study, several metal-
lothionein genes (MT1H, MT1X, MT1G, MT2A, MT1M,
MT1E, MT1F) were overexpressed (2.6 to 3.8 times) fol-
lowing IL-2 withdrawal. In addition, we show here, that
Cyclin D expression, reported to be downregulated by
FOXO and KLF [1,35], decreased after IL-2 withdrawal.
However, some genes reported by other research groups as
human FOXO targets, such as p130 gene, Cyclin G2 [37],
or IGF1R, BCL-2BP, or Sestrin 1 found to be FOXO3a-
inducible genes in mouse T cells [34], as well as most of
the KLF targets summarised by Tsachanis [16] and Yusuf
[33], were unaffected by IL-2 deprivation in our experi-
mental model.
A set of genes identified as significantly down-regulated 8
hours following IL-2 withdrawal included PIM1, BCL2,
IL-8, HBEGF, DUSP6, OSM, CISH, SOCS2, LIF and IL13.
It is notable that some of the identified genes, namely
PIM1, BCL2, DUSP6, CISH and SOCS2 were previously
demonstrated to be the IL-2 target genes or the regulators
of IL-2 signalling [39-41]. In addition, it is clear that
PIM1, CISH and suppressors of cytokine signalling
(SOCS) are implicated in the biological actions of IL-2
[42], and that IL-2 was found to regulate mRNA levels of
SOCS2, CISH, DUSP5 and DUSP6 [41]. It has also been
demonstrated that OSM can quickly up-regulate CISH
[43]. The coordinated repression of OSM and CISH that
we showed in T cells following IL-2 withdrawal is consist-
ent with these observations.
To perform a functional analysis of the up- and down-reg-
ulated genes, the 158 genes selected in the non-paired
comparison between IL-2-deprived and non-deprived
lymphocytes were first analysed by Gene Ontology (GO)
Categories (see Additional File 3. Table A3 for gene ontol-
ogy analysis of genes selected in a non-paired sample
comparison between IL-2-deprived and non-deprived
lymphocytes). The number of genes changed in each cat-
egory was compared with the expected quantity of genes
and the greatest enrichment was found in two molecular
function (MF) classes, GO:0016868, intramolecular
transferase activity, phosphotransferases; (observed/
expected ratio = 43.9) and GO:0005126, hematopoietin/
interferon-class (D200-domain) cytokine receptor bind-
ing, (observed/expected ratio = 26.3) and two biological
process (BP) classes, GO:0007259, JAK-STAT cascade
(observed/expected ratio = 16.7) and GO:0009968, nega-
tive regulation of signal transduction, (observed/expected
ratio = 6.8). Secondly, a gene set analysis was performed
by comparing the overall significance of gene groups
defined by GO categories. Out of the 2348 GO classes 317
were found to be significantly affected by IL-2 withdrawal,
as shown by at least one of the three tests used to assess
the significance of the differences. The selected GO catego-
ries are shown in Table 3. The LS/KS permutation tests,
which find gene sets that have more differentially
expressed genes among the classes than expected by
chance, identified 206 significant gene-sets. Efron-Tib-
shirani's test, which uses 'maxmean' statistics to identify
differentially expressed gene-sets, found 231 significant
gene-sets (under 200 permutations). Eleven out of the
215 cellular component categories, 69 of 545 molecular
function (MF) categories and 237 of 1588 biological proc-
ess (BP) categories were significant. Thirty-nine GO cate-
gories with p < 0.005 in all of the three applied gene group
significance tests were identified (see Additional File 4:
Table A4 for overall significance of expression changes fol-
lowing IL-2 deprivation in gene groups defined by GO cat-
egories).
The same analytical procedure applied to the database of
biological pathways (Biocarta, human database) resulted
in 54 significantly up-regulated gene sets. Selected path-
ways affected by IL-2 withdrawal are shown in Table 4.
Both analyses, GO and Biocarta, confirmed the consistent
up-regulation of the genes belonging to the JAK-STAT
pathway.
Our data demonstrate for the first time that IL-2 with-
drawal induces a coordinate repression of the same set of
genes that have been found to be induced during T cell
activation as IL-2 targets [44,45]. A similar "symmetry"
has been previously shown in human fibroblasts, where
approximately half of the genes of the early response to
serum stimulation were correspondingly repressed at the
cell cycle exit after mitogen deprivation [17].
A few previous studies have shown that some mRNAs that
are expressed in resting T and B lymphocytes become
repressed following cell activation, and it was suggested
that cell quiescence is under an active transcriptional con-
trol [1]. Similarly, as shown recently, exit from the cell
cycle of human fibroblasts is under control of a "quies-B
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Table 2: Gene expression signature of T lymphocyte cell cycle exit.
Probe set Gene symbol Description Fold-change (after IL-2 
withdrawal vs. before)
Paired design Non-paired design
Parametric 
p-value
FDR1 Parametric p-value FDR
Up-regulated
1 1555878_at RPS24 ribosomal protein S24 3.21 0.0003 0.30 <0.0001 0.03
2 201471_s_at SQSTM1 sequestosome 1 2.48 0.0002 0.30 0.0004 0.09
3 226831_at NA NA 2.04 0.0004 0.30 <0.0001 <0.01
4 1555446_s_at TMEM1 transmembrane protein 1 2.04 <0.0001 0.30 <0.0001 <0.01
5 218684_at LRRC8D leucine rich repeat containing 8 
family, member D
1.72 0.0007 0.30 0.0003 0.09
6 208091_s_at ECOP EGFR-coamplified and 
overexpressed protein
1.69 0.0006 0.30 <0.0001 0.06
7 244803_at YY1AP1 YY1 associated protein 1 1.66 0.0002 0.30 0.0004 0.09
8 209006_s_at C1orf63 chromosome 1 open reading 
frame 63
1.65 0.0006 0.30 0.0007 0.10
9 213702_x_at ASAH1 N-acylsphingosine amidohydrolase 
(acid ceramidase) 1
1.59 <0.0001 0.30 <0.0001 0.02
10 212833_at SLC25A46 solute carrier family 25, member 
46
1.58 0.0006 0.30 0.0005 0.10
11 212310_at MIA3 melanoma inhibitory activity 
family, member 3
1.50 0.0007 0.30 <0.0001 0.03
12 1562612_at ME2 malic enzyme 2, NAD(+)-
dependent, mitochondrial
1.47 <0.0001 0.309 <0.0001 <0.01
13 230161_at CD99 CD99 molecule 1.45 0.0005 0.30 <0.0001 <0.01
Down-regulated
1 1553101_a_at ALKBH5 alkB, alkylation repair homolog 5 
(E. coli)
0.72 0.0003 0.23 0.0009 0.11
2 201968_s_at PGM1 phosphoglucomutase 1 0.64 0.0006 0.22 0.0006 0.10
3 206055_s_at SNRPA1 small nuclear ribonucleoprotein 
polypeptide
0.62 0.0005 0.22 0.0005 0.10
4 228146_at C17orf51 chromosome 17 open reading 
frame 51
0.55 0.0007 0.22 0.0007 0.10
5 207339_s_at LTB lymphotoxin beta 
(TNF superfamily, member 3)
0.54 0.0002 0.22 0.0008 0.11
6 201170_s_at BHLHB2 basic helix-loop-helix domain 
containing, class B, 2
0.53 <0.0001 0.22 <0.0001 0.04
7 202932_at YES1 v-yes-1 Yamaguchi sarcoma viral 
oncogene homolog 1
0.50 0.0008 0.224 0.0009 0.11
8 206999_at IL12RB2 interleukin 12 receptor, beta 2 0.49 0.0002 0.22 0.0005 0.10
9 201041_s_at DUSP1 dual specificity phosphatase 1 0.44 0.0005 0.21 <0.0001 0.05B
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10 202081_at IER2 immediate early response 2 0.43 0.0005 0.21 0.0009 0.11
11 227262_at HAPLN3 hyaluronan and proteoglycan link 
protein 3
0.41 0.0005 0.20 0.0006 0.10
12 218551_at RP5-1077B9.4 invasion inhibitory protein 45 0.41 0.0004 0.20 0.0006 0.10
13 212590_at RRAS2 related RAS viral (r-ras) oncogene 
homolog 2
0.40 0.0002 0.20 0.0002 0.07
14 226283_at WDR51B WD repeat domain 51B 0.39 0.0004 0.20 <0.0001 0.01
15 219681_s_at RAB11FIP1 RAB11 family interacting protein 1 
(class I)
0.38 0.0004 0.20 <0.0001 0.03
16 219255_x_at IL17RB interleukin 17 receptor B 0.38 0.0004 0.20 0.0005 0.10
17 224156_x_at IL17RB interleukin 17 receptor B 0.37 0.0007 0.20 0.0006 0.10
18 210845_s_at PLAUR plasminogen activator, urokinase 
receptor
0.36 0.0004 0.20 0.0003 0.08
19 214508_x_at CREM cAMP responsive element 
modulator
0.30 0.0007 0.20 <0.0001 0.05
20 209488_s_at RBPMS RNA binding protein with multiple 
splicing
0.28 0.0007 0.20 <0.0001 0.05
21 223217_s_at NFKBIZ nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells inhibitor, zeta
0.25 0.0008 0.20 0.0005 0.10
22 209193_at PIM1 pim-1 oncogene 0.20 <0.0001 0.20 <0.0001 <0.01
23 225262_at FOSL2 FOS-like antigen 2 0.17 0.0004 0.20 0.0006 0.10
24 227599_at C3orf59 chromosome 3 open reading 
frame 59
0.17 <0.0001 0.19 <0.0001 <0.01
25 244035_at BCL2 B-cell CLL/lymphoma 2 0.16 0.0008 0.19 0.0009 0.11
26 202859_x_at IL8 interleukin 8 0.15 0.0009 0.19 0.0006 0.10
27 211506_s_at IL8 interleukin 8 0.10 0.0003 0.19 0.0002 0.07
28 203821_at HBEGF heparin-binding EGF-like growth 
factor
0.06 0.0004 0.19 0.0002 0.07
29 207844_at IL13 interleukin 13 0.05 <0.0001 0.19 0.0007 0.10
30 214637_at OSM oncostatin M 0.05 0.0002 0.18 <0.0001 <0.01
31 203373_at SOCS2 suppressor of cytokine signaling 2 0.04 0.0001 0.17 <0.0001 0.03
32 205266_at LIF leukemia inhibitory factor 
(cholinergic differentiation factor)
0.04 0.0003 0.17 <0.0001 0.03
33 203372_s_at SOCS2 suppressor of cytokine signaling 2 0.03 0.0002 0.17 <0.0001 0.03
34 208891_at DUSP6 dual specificity phosphatase 6 0.03 0.0002 0.17 <0.0001 <0.01
35 223377_x_at CISH cytokine inducible SH2-containing 
protein
0.03 <0.0001 0.16 <0.0001 <0.01
36 223961_s_at CISH cytokine inducible SH2-containing 
protein
0.03 <0.0001 0.14 <0.0001 0.01
37 221223_x_at CISH cytokine inducible SH2-containing 
protein
0.03 <0.0001 0.13 <0.0001 <0.01
38 208893_s_at DUSP6 dual specificity phosphatase 6 0.02 <0.0001 0.13 <0.0001 <0.01
39 230170_at OSM oncostatin M 0.02 0.0002 0.13 <0.0001 <0.01
40 208892_s_at DUSP6 dual specificity phosphatase 6 0.02 0.0010 0.05 <0.0001 0.03
Common genes identified as significantly changed (p < 0.001) in a paired analysis and in a non-paired block analysis.
1FDR – False Discovery Rate
Table 2: Gene expression signature of T lymphocyte cell cycle exit. (Continued)BMC Genomics 2009, 10:261 http://www.biomedcentral.com/1471-2164/10/261
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cence program" dependent upon a set of genes that
enforce the non-dividing state, and ensure the reversibility
of the cell cycle arrest [15,17]. Our data support the idea
of cell cycle arrest as an active state, controlled by some
up-regulated genes.
While in vitro T lymphocytes deprived of a growth factor
would eventually undergo apoptosis, in vivo a small pro-
portion of antigen-activated cells would exit to G0 and
become quiescent. Cellular quiescence is thought to be an
indispensable state for the maintenance of lymphocyte
homeostasis following immune response, and therefore it
is an important barrier against tumorigenesis [46-48].
Some autoimmune and chronic inflammatory disorders
involving an excessive lymphocyte proliferation, were
found to be associated with increased risks of lymphoma
[44,45]. Thus, it is very likely that a deregulated expression
of genes responsible for cellular quiescence may contrib-
ute to the development of some lymphoid malignancies.
To assess whether T cells adopt quiescent, memory cell
phenotype upon IL-2 withdrawal in our model, we com-
pared the gene expression patterns obtained with those
described by other researchers as characterising memory
vs. naïve vs. effector T cells. Two molecules known to facil-
itate T cell homing to lymphoid tissues, SELL (CD62L)
and CCR7 are expressed predominantly by naïve and
memory T cells [49-52], but CCR7 expression seems not
to be affected by growth factor withdrawal [52]. In our
model of cell cycle exit the SELL gene was up-regulated in
primary T cell lines, while CCR7, was unchanged in pri-
mary T cells and slightly down-regulated in immortalised
T cells after IL-2 deprivation. Out of other genes identified
by Holmes et al. [49] as up-regulated in memory T cells, T
cells deprived of IL-2 overexpressed SMAD3, TRIM66 and
NAP1L3. There was also an increased expression of IL7R,
thought to be expressed in memory [53] and naïve
[50,52] T cells, but this was found not significant by the
qRT-PCR (Table 1) when analysed for all T cells, possibly
because this was truth only in primary T cells. The CD58
(LFA3) gene, encoding an adhesion molecule known to
be expressed on activated and memory T cells [54], was
indeed highly expressed in actively growing cells and con-
sistently up-regulated after IL-2 withdrawal in our experi-
mental system.
Holmes et al. [49] reported Granzyme B and  KLRD1
expression to be induced in activated T cells. Our experi-
ments showed that growth factor-deprived T cells pre-
sented decreased Granzyme B expression, while KLRD1
expression was slightly upregulated, but only in primary T
cells. A hierarchical clustering of some genes outlined by
Holmes et al. [49] is shown in an Additional file 5: Figure
A1.
Haining et al. [55] demonstrated a gene expression profile
common for CD8 and CD4 memory T cells. We showed
that some of the genes of this profile were significantly
changed at cell cycle exit; there was an increased expres-
sion of S100A4, S100A11, ANXA1, ANXA2, CRIP1 and
CASP1, which, according to Haining et al. [55], are up-reg-
ulated in memory T cells, and a reduced expression of
Granzyme A, downregulated in memory cells [55].
In summary, T cells withdrawn from cell cycle gained
some crucial characteristics of memory T cells. Neverthe-
less, the cell cycle exit signature that we describe here is
different from memory T cell gene expression signatures
published so far.
Further studies will reveal whether there is a common
mechanism of quiescence for different cell types, such as
the "common quiescence program" in fibroblasts stimu-
lated to exit to G0 by different stimuli [15]. Interestingly,
it has been found recently that a group of genes required
for cell cycle exit in human fibroblasts following serum
deprivation, were coordinately repressed in many types of
human cancers, and repression of these genes predicted
an increased risk of cancer progression and death in breast
cancer patients [17]. Our studies on a model of human
primary and immortalised IL-2-dependent T lymphob-
lasts extended these observations and brought new
insights into the understanding of molecular events
important in cell cycle exit, deregulation of which may
relate to cancer development.
Conclusion
Cell cycle exit of growth factor-deprived primary and
immortalised T lymphocytes is characterised by a gene
expression signature, comprising 13 up-regulated and 40
down-regulated genes. Some of these genes are implicated
in the mechanisms of cell growth control and show dereg-
ulated expression in different tumours. The gene set iden-
tified in the non-paired analysis was enriched in
transcription, cell cycle, cell growth, proliferation and dif-
ferentiation, cell adhesion, and immune function genes.
Cells at cell cycle exit seem to be under an active transcrip-
tional control. Upon IL-2 withdrawal, some genes become
repressed, including those known to be induced during T-
cell activation, while others become up-regulated. The
identification of genes involved in cell cycle exit and qui-
escence provides new hints for further studies on the
molecular mechanisms regulating the non-dividing state
of a cell, the mechanisms closely related to cancer devel-
opment and to many biological processes.
Methods
Cell sources and cell sample preparation
Primary, IL-2-dependent T lymphoblast cell lines ("6",
"43" and "j") were generated and propagated as previ-BMC Genomics 2009, 10:261 http://www.biomedcentral.com/1471-2164/10/261
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ously described [56]. Briefly, peripheral blood mononu-
clear cells (PBMC) derived from three healthy donors
("6", "43" and "j") were suspended in a standard medium
(RPMI 1640, 10–12% FCS, 50 μg/ml gentamycin
[Sigma]), activated for 24 h with 20 μg/ml of wheat germ
agglutinin (Pharmacia) and subsequently cultured in the
standard medium supplemented with 20 U/ml of recom-
binant (r) IL-2 (R&D). Flow cytometry cell surface analy-
sis showed that the three primary T lymphoblast cell
populations were composed of T cells exclusively, as they
expressed all the pan-T markers, and a subset of the cells
also expressed CD4 or CD8 surface molecules (unpub-
lished data).
Viable cells were assessed every 3–7 days by the trypan
blue exclusion test and resuspended to the concentration
of 0.5–2.0 × 105 cells/ml in a fresh standard medium sup-
plemented with rIL-2. The number of population dou-
blings (PD) was calculated according to the formula:
The cells "6", "43" and "j" were collected after 4–5, 7–8
and 6–7 PD, respectively. The samples of the three pri-
mary cell lines were analysed as biological replicates.
Spontaneously immortalised IL-2-dependent T cell lines
were derived from normal spleen (line 5) and from PBMC
derived from a Nijmegen Breakage Syndrome patient
(line S9), as previously described [56,57]. Samples of the
immortalised cell lines were collected in three biological
replicates each.
PD
Final viable cell number
Initial cell number
=×
− ln [ln ] 2
1
Table 3: Selected Gene Ontology GO categories significantly affected by genes deregulated following IL-2 deprivation.
GO category GO 
categories
GO term LS 
permutation 
p-value
KS 
permutation 
p-value
Efron-
Tibshirani's 
GSA test
p-value
Up-regulated 
genes
(p < 0.01)
Down-
regulated 
genes
(p < 0.01)
GO:0004907 MF interleukin 
receptor activity
0.00001 0.00001 < 0.005 IL12RB1, IL7R IL2RA, IL12RB2, 
IL17RB IL1RAP
GO:0019955 MF cytokine binding 0.00001 0.00001 < 0.005 IL12RB1, IL7R IL2RA, IL12RB2, 
IL17RB IL1RAP
GO:0004896 MF hematopoietin/
interferon-class 
(D200-domain) 
cytokine receptor 
activity
0.00001 0.0000988 < 0.005 IL12RB1, IL7R IL2RA, IL12RB2, 
IL17RB IL1RAP
GO:0007259 BP JAK-STAT 
cascade
0.00001 0.0001056 < 0.005 SOCS1, SOCS2, 
SOCS3, OSM, 
STAT4
GO:0006959 BP humoral immune 
response
0.00001 0.0006364 < 0.005 BCL2, CD55, 
CFHR1, TNF, 
LTA, CFH, BCL3, 
GPI
GO:0050900 BP leukocyte 
migration
0.00001 0.0047229 < 0.005 MYH9 IL8, TNF, CKLF, 
ITGB2
GO:0017040 MF ceramidase 
activity
0.00001 0.0049829 < 0.005 ASAH1
GO:0018108 BP peptidyl-tyrosine 
phosphorylation
0.0001871 0.0032075 < 0.005 CLK4 OSM, SOCS1, IL5, 
ITGB2
GO:0006672 BP ceramide 
metabolic 
process
0.0004208 0.0030228 < 0.005 ASAH1 UGCG, CLN8
GO:0007260 BP tyrosine 
phosphorylation 
of STAT protein
0.0004601 0.0046325 < 0.005 OSM, SOCS1
GO:0030218 BP erythrocyte 
differentiation
0.0013289 0.00001 < 0.005 FOXO3, BCL6 SFXN1
GO:0042379 MF chemokine 
receptor binding
0.001562 0.0008411 < 0.005 IL8, CCL3, CKLF
GO:0048660 BP regulation of 
smooth muscle 
cell proliferation
0.003213 0.0021998 < 0.005 HBEGF
Three independent tests: LS, KS and Efron-Tibshirani GSA were applied to select significantly affected gene classes.B
M
C
 
G
e
n
o
m
i
c
s
 
2
0
0
9
,
 
1
0
:
2
6
1
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
1
6
4
/
1
0
/
2
6
1
P
a
g
e
 
1
1
 
o
f
 
1
5
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 4: A selection of significantly impacted pathways (BioCarta) in T lymphocytes following IL-2 deprivation.
Pathway description Biocarta Pathway LS permutation
p-value
KS permutation
p-value
Efron-Tibshirani's 
GSA test p-value
Up-regulated genes 
(p < 0.01)
Down-regulated 
genes
(p < 0.01)
Visceral Fat Deposits and 
the Metabolic Syndrome
h_vobesityPathway 0.00001 0.0001273 < 0.005 NR3C1 TNF, HSD11B1
Cells and Molecules 
involved in local acute 
inflammatory response
h_LairPathway 0.00001 0.0007952 < 0.005 ITGB1, ITGAL IL8, TNF, ICAM1, ITGA4
Adhesion and Diapedesis 
of Lymphocytes
h_lympathway 0.00001 0.0029985 < 0.005 ITGB1, ITGAL IL8, ICAM1, ICAM2, ITGA4
Adhesion and Diapedesis 
of Granulocytes
h_granulocytesPathway 0.00001 0.0032844 < 0.005 IL-8, TNF, CD54, ICAM2
Cytokine Network h_cytokinePathway 0.00001 0.0297027 < 0.005 IL13, IL8, LTA, IL-5
IL-2 Receptor Beta Chain 
in T cell Activation
h_il2rbPathway 0.00001 0.030315 < 0.005 CISH, IL2RA, SOCS3, BCL2, 
AKT1, JAK3
Induction of apoptosis 
through DR3 and DR4/5 
Death Receptors
h_deathPathway 0.00001 0.00001 0.06 BCL2, TRADD
IL22 Soluble Receptor 
Signaling Pathway
h_il22bppathway 0.0000955 0.00001 < 0.005 SOCS3, JAK3
Selective expression of 
chemokine receptors 
during T-cell polarization
h_nktPathway 0.0000994 0.0000936 0.03 IL12RB1, CCR4 ILRB2, CCL3, IL5
Cytokines and 
Inflammatory Response
h_inflamPathway 0.0001717 0.078942 < 0.005 IL13, IL8, TNF, LTA, IL5
NO2-dependent IL 12 
Pathway in NK cells
h_no2il12Pathway 0.0006013 0.0135205 < 0.005 IL12RB1, CD2 IL12RB2
Regulation of MAP Kinase 
Pathways Through Dual 
Specificity Phosphatases
h_dspPathway 0.0007988 0.1717258 < 0.005 DUSP6, DUSP1
PTEN dependent cell 
cycle arrest and apoptosis
h_ptenPathway 0.0015749 0.0100088 < 0.005 FOXO3, ITGB1, MAPK1 AKT1, PDK1, SOS1
Ceramide Signaling 
Pathway
h_ceramidePathway 0.0016286 0.005673 < 0.005 MAPK1 BCL2, TRADD
Th1/Th2 Differentiation h_th1th2Pathway 0.001734 0.0676275 0.07 IL12RB1 IL2RA, IL12RB2
Dendritic cells in 
regulating TH1 and TH2 
Development
h_dcPathway 0.0023595 0.0493208 < 0.005
p53 Signaling Pathway h_p53Pathway 0.0026524 0.1802796 < 0.005 BCL2, CDK2, CDKN1A
Telomeres, Telomerase, 
Cellular Aging, and 
Immortality
h_telPathway 0.0367325 0.3499152 < 0.005 BCL2, AKT1
Phospholipids as signalling 
intermediaries
h_edg1Pathway 0.0404929 0.1894782 < 0.005 ASAH1 AKT1
Testing of 288 Biocarta human pathways identified 54 out of 288 investigated gene-sets that passed the 0.005 significance threshold in at least one test (38 gene-sets in LS/KS test and 36 in Efron-
Tibshirani's test).BMC Genomics 2009, 10:261 http://www.biomedcentral.com/1471-2164/10/261
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The differential gene expression analysis was performed in
cell samples collected directly from the IL-2-containing
cultures (samples: 6/0, 43/0, j/0, line 5/0 and S9/0) and
after 8-hrs incubation of the lymphoblasts in a standard
medium without IL-2, following triple thorough washing
of the cells in a standard medium (samples: 6/8, 43/8, j/
8, line 5/8 and S9/8). In the cultures deprived of IL-2 for
8 hours, no apoptosis was observed in the primary T lym-
phoblast lines, and in the immortalised cell lines a negli-
gible proportion of cells had the characteristics of early
apoptotic cells, as detected by flow cytometry following
Annexin-V staining with the use of the Annexin-V-FLUOS
Staining Kit of ROCHE (Table 5). But S-phase depletion
and G1/S block were observed, as evaluated by flow
cytometry with the use of the BD Cycletest Plus (Becton
Dickinson) (unpublished data).
Microarray procedures
Total RNA was isolated using Nucleospin RNA II kit
(Macherey-Nagel, Germany). RNA quality was assessed
using the Agilent 2100 Bioanalyzer and RNA 6000 Nano
Chip Kit (Agilent Technologies).
The Affymetrix GeneChip Human Genome U133 Plus 2.0
arrays, which measure the expression level of over 47,000
transcripts and variants, including 38,500 well-character-
ised human genes, were used. cDNA synthesis was carried
out from 5 μg of RNA (One-Cycle cDNA Synthesis Kit,
Affymetrix). After purification (GeneChip Sample
Cleanup Module), 7 μl of double-stranded cDNA were
used for biotinylated cRNA synthesis (IVT Labeling Kit,
Affymetrix). Labeled cRNA was purified using a GeneChip
Sample Cleanup Module, fragmented and hybridised
with genome array. Washing, staining with streptavidin-
phycoerythrin conjugate and scanning of the arrays in
Affymetrx GeneChip 3000 scanner were performed as rec-
ommended by the Affymetrix Gene Expression Analysis
Technical Manual.
Data analysis
All 18 arrays were normalised by the GC-RMA algorithm
using a Bioconductor gcrma package. We filtered out all
genes with small amplitude of differences (less than 10%
of samples with at least 1.5-fold difference in either direc-
tion from the median gene expression among all sam-
ples). The filtered dataset comprised of 18770 probe-sets.
The full dataset has been deposited in the Gene Expres-
sion Omnibus repository (accession no GSE13909).
Differentially expressed genes were identified by a ran-
dom-variance t-test, with the statistical significance
threshold set at p < 0.001. A stringent significance cut-off
was used to limit the number of false positive genes
obtained (at this threshold no more than 19 false posi-
tives are expected in each analysis). A global test of the dif-
ferences in expression profiles between the classes was
also performed by sample permutation. Simultaneously,
we assessed a False Discovery Rate for each probeset using
the Benjamini-Hochberg method.
To examine the effects of IL-2 withdrawal, samples were
compared either according to the type of the cell line (pri-
mary/immortalised) in a block design or in a paired sam-
ple t-test analysis (for this analysis the replicates of the
same sample were averaged).
For cluster analysis, genes identified in the non-paired
analysis were used to obtain a heatmap plot with dendro-
grams, using Ward's hierarchical cluster algorithm (Bio-
conductor).
Gene Ontology classes for the resulting lists of genes were
compared to the number of genes expected, considering
the number of genes on the microarray in each category.
GO classes and parent classes with at least 5 observations
in the selected subset and with an observed vs expected
ratio of at least 2 were analysed.
The statistical significance of global gene expression
changes in gene ontology categories and BioCarta path-
ways was assessed by LS/KS permutation tests and the
Efron-Tibshirani's GSA maxmean test. All data analyses
were performed using the BRB-ArrayTools (developed by
Dr. Richard Simon and BRB Array Tools development
team) or by Bioconductor packages.
Real time RT-PCR validation of gene expression
Based on the microarray results, the following genes were
selected for validation by the real-time RT-PCR technique:
DUSP6, ASAH1, HBEGF, MT1F, MT1X, IL7R, IL8, CLK4,
C3orf59, SOCS2, OSM and CISH. Specific primers were
Table 5: Percentages of apoptotic and necrotic cells in cultures 
of IL-2-dependent primary (j, 43) and immortalised (line 5, S9) T 
lymphoblasts (0 h) and at different time points after IL-2 
withdrawal (2 h, 8 h, 24 h), analysed by flow cytometry following 
Annexin-V staining.
Cell lines 0 h1 2 h 8 h 24 h
A2 N3 ANANAN
j0 . 2 4 2.1 0.9 1.1 0.4 2.2 0.5 2.0
43 0.5 3.0 0.7 2.0 0.4 2.2 0.7 3.0
line 5 2.3 4.0 3.8 2.3 4.6 2.0 8.1 3.8
S9 5.4 1.3 6.7 1.3 8.4 1.5 6.9 1.1
1hours after IL-2 withdrawal
2A – apoptosis
3N – necrosis
4percentage; mean of two replicatesBMC Genomics 2009, 10:261 http://www.biomedcentral.com/1471-2164/10/261
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designed using Primer Express v.2.0 software (Applied
Biosystems). Detailed primer sequences are available on
request.
The cDNA was synthesised with the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems) using 1 μg
of total RNA as a template, and Oligo-dT-Primers
(Applied Biosystems), according to the manufacturer's
instructions. The real-time (= quantitative, q) RT-PCR
reactions were performed with Power SYBR Green PCR
Master Mix (Applied Biosystems) using the 7000 Real-
Time PCR system (Applied Biosystems). Reaction mix-
tures (25 μl) were subjected to a two-step program: 95°C
for 10 minutes followed by 40 cycles of 95°C for 15 s and
60°C for 1 minute. The data were analysed using ABI
PRISM 7000 SDS Software. The relative fold difference in
gene expression was calculated by the ΔΔCt method using
the ACTB gene as a normalisation control. The statistical
significance of the fold change was assessed by the
ANOVA test (Statistica package).
Abbreviations
BP: biological process; GO: gene ontology; IL: interleukin;
MF: molecular function; PBMC: peripheral blood mono-
nuclear cells; r: recombinant.
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